Pfizer has launched Zavicefta (ceftazidime-avibactam) for adults hospitalised with serious infections caused by aerobic Gram-negative bacteria. Zavicefta combines the beta-lactam antibiotic ceftazidime with the beta-lactamase inhibitor, avibactam.

Pfizer says that ceftazidime-avibactam is effective against some “resistant aerobic Gram-negative pathogens of greatest global concern”, such as carbapenem-resistant Enterobacteriaceae and multi-drug resistant Pseudomonas aeruginosa.

Recommended

Verapamil for rhinosinusitis?

Verapamil dramatically improves symptom scores in patients with chronic rhinosinusitis and nasal polyps

NSAIDs and paracetamol linked to hearing loss

NSAIDs and paracetamol might increase the risk of hearing loss, according to an analysis of 55,850 women

Popular

PSNC paints pessimistic picture for the future

The impact of the funding cuts in England is going to hit contractors hard in November, PSNC has warned

Schools now able to purchase AAIs

Schools can now purchase adrenaline auto-injectors without a prescription for emergency use

Are there barriers to women leaders in pharmacy?

With a number of pharmacy organisations with few or no women on their elected boards, what might be stopping more women ...